An interventional study of Visual Saline Infusion and Hydrosonography in Hysteroscopy, Hysteroscopy Technique and Fertility Issues, sponsored by Center for Reproductive Health & Gynecology. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by Center for Reproductive Health & Gynecology · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 24 under way, none of them phase 3. Infertility, Female · United States.
Among the 65 studies in Infertility, Female with a site in United States, this one is the 16th largest by planned enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2024, is one of 30 with no phase, reaches primary completion later than 6 of the 23 other live ones, and was the 53rd registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
Shady Grove Fertility Reproductive Science Center · Sites in United States
Women only
University of Southern California · Sites in United States
Ages 18–44 · Women only
University of Colorado, Denver · Sites in United States
Ages 18–38 · Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4 · Phase 4 6
First in 2004; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 50 across the 47 interventional studies, 175 across the 18 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 65 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Center for Reproductive Health & Gynecology as lead sponsor.
Center for Reproductive Health & Gynecology has 1 study filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
5 of the studies in Infertility, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06434233Johns Hopkins UniversityOpioid Use After Laparoscopic Salpingectomy | 2026-11 |
| NCT05997407Virginia Polytechnic Institute and State UniversityThe Effect of a Mindset Management Approach on Stress Levels in Women With Infertility | 2026-12 |
| NCT07858435New Hope Fertility CenterIntra-ovarian CAPA-IVM vs Standard IVM | 2027-03 |
| NCT06686537University of Colorado, DenverConvergent Mechanisms Underlying Reprometabolic Syndrome in Women | 2027-10 |
| NCT04628507Genomic Prediction Inc.Cell Free Preimplantation Genetic Testing | 2027-11-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 65 studies in Infertility, Female with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single center, multiple arm cohort study intended to compare the diagnostic accuracy of a Visual Saline Infusion Device (VSI) device, vs standard of care Hydrosonography in reproductive aged women to identify pathology in the uterus.
This is a prospective, single center, multiple arm cohort study intended to compare the diagnostic accuracy of a Visual Saline Infusion Device (VSI) device, vs standard of care Hydrosonography in reproductive aged women to identify pathology in the uterus.
Patients who are enrolled in the study will have a 1) Hydrosonography, and 2) Visual Saline Infusion procedure performed.
The Visual Saline Infusion Device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
This study will recruit up to 100 women from a fertility center in Los Angeles.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 378 interventional studies indexed under Infertility, Female.
Browse Infertility, Female studies →This is the only study on the registry with Center for Reproductive Health & Gynecology as lead sponsor.
Compared within Infertility, Female, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1a. Chlamydial pelvic infection
1b. Gonorrheal pelvic infection. 2. Positive Pregnancy Test 3. IUD currently in place
Visual Saline Infusion is intended to perform direct visual evaluation of the intrauterine space using a 2.7mm, steerable tip catheter with a camera.
Device: Visual Saline Infusion
Hydrosonography is the standard of care for intrauterine evaluation. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus, and using abdominal ultrasound to detect intrauterine pathology.
Device: Hydrosonography
Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
Intrauterine pathology detection rate with Hydrosonography
The assessment will involve the examination of the intrauterine cavity for the presence of pathologies, including polyps, fibroids, adhesions, scar tissue, thickened endometrium, among others. The detection rate will be calculated as the ratio of the number of cases where abnormal pathologies are identified to the total number of cases examined.
Time frame: Procedure of 2-5 minute duration
Intrauterine pathology detection rate with Visual Saline Infusion
The assessment will involve the examination of the intrauterine cavity for the presence of known pathologies, including polyps, fibroids, adhesions, scar tissue, thickened endometrium, among others. The detection rate will be calculated as the ratio of the number of cases where abnormal pathologies are identified to the total number of cases examined.
Time frame: Procedure of approximately 2-5 minute duration
Visual detection quality score (1-10)
The visual detection quality score will be assessed using a normalized scale ranging from 1 (indicating poor or no visualization) to 10 (indicating excellent visualization), with scores assigned based on the clarity and detail of the intrauterine images obtained during the examination.
Time frame: Captured during procedure
Fluid used during distention
The volume of fluid used for distention of the uterus will be documented.
Time frame: Captured during procedure
Pain during procedure
The research team will interview the Subject and record the level of pain experienced based on the Wong Baker pain scale
Time frame: Collected on day of procedure
Adverse events rate
Anticipated and unanticipated adverse events will be documented
Time frame: Day of procedure and 24-48 hours post to procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for May 2025, 12 months after the start.
Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 12 months is below that.
Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.